#Canada #Clinical Trial #Research Triangle Park #Bantam Pharmaceutical #BTM-3566

Bantam Pharmaceutical Expands BTM-3566 Clinical Trial into Canada

Bantam Pharmaceutical, a drug discovery and development firm focused on innovative cancer therapies, has taken significant steps in its clinical research program. The company is scaling its Phase 1 trial of BTM-3566 beyond the U.S. and into Canada, following approval from Health Canada. This expansion is part of Bantam's strategy to enhance recruitment and research capacity for the treatment of mature B-cell lymphomas, which include various aggressive forms of cancer.

Bantam's latest move allows for the opening of multiple clinical sites across Canada, effectively increasing the pace of data collection and patient involvement. The involvement in the Canadian clinical landscape will start early in the second quarter of 2025, which Bantam anticipates will help expedite the trial outcomes. Michael Stocum, President and CEO of Bantam Pharmaceutical, emphasized the importance of activating these sites as it brings an efficiency to the clinical program while ensuring scientific integrity.

The BTM-3566 trial is pivotal, designed to assess both the safety and preliminary effectiveness of this novel therapeutic compound which acts on mitochondrial dynamics through the ATF4-Integrated Stress Response pathway. BTM-3566 is receiving attention due to its distinct mechanism which allows for potential treatment of not just hematologic cancers but also solid tumors in future phases. Bantam's decision to conduct trials across two countries aims to harmonize data collection processes, thereby creating a robust information framework for understanding the drug's effects.

The active U.S. trial site at The University of Texas MD Anderson Cancer Center has laid the groundwork for this expansion. With initial findings anticipated in the latter half of 2025, Bantam is set on a pathway to explore the clinical landscape of aggressive B-cell malignancies, including mantle cell lymphoma and diffuse large B-cell lymphoma. BTM-3566's capabilities, as shown in previous studies, indicate significant anti-cancer properties, with some subjects exhibiting complete tumor regression where typical therapies fell short.

In the preclinical setting, this therapy demonstrated a remarkable ability to induce apoptosis, or programmed cell death, in resistant tumor cells. The company's approach to targeting fundamental cancer processes aligned with patient needs bodes well for its future in both hematologic and solid tumors.

Bantam Pharmaceutical remains focused on expanding its investigational capabilities as supported by its Investigational New Drug (IND) and Clinical Trial Application (CTA), which affirm its dedication to addressing unmet medical needs in the oncology sector. As cancer research advances, the integration of international clinical trials showcases the evolving landscape of care options for patients with limited alternatives.

For ongoing updates, interested individuals can track the clinical trial on ClinicalTrials.gov by searching for NCT06792734. Bantam Pharmaceutical's mission leads towards creating impactful, first-in-class therapies that make a significant difference for patients facing daunting cancer challenges.

About Bantam Pharmaceutical

Bantam Pharmaceutical develops innovative treatment solutions through understanding mitochondrial dynamics, aiming to meet critical oncology demands. With a focus on hematological and solid tumors, the company is emerging as a leader in the onco-pharmaceutical landscape, determined to transform patient care through groundbreaking science.